ATE476188T1 - Medikament zur prävention und behandlung von familiärer amyloid polyneuropathie - Google Patents

Medikament zur prävention und behandlung von familiärer amyloid polyneuropathie

Info

Publication number
ATE476188T1
ATE476188T1 AT03723352T AT03723352T ATE476188T1 AT E476188 T1 ATE476188 T1 AT E476188T1 AT 03723352 T AT03723352 T AT 03723352T AT 03723352 T AT03723352 T AT 03723352T AT E476188 T1 ATE476188 T1 AT E476188T1
Authority
AT
Austria
Prior art keywords
treatment
drug
prevention
amyloid polyneuropathy
amyloidosis
Prior art date
Application number
AT03723352T
Other languages
English (en)
Inventor
Hirofumi Kai
Yukio Ando
Original Assignee
Nipro Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nipro Corp filed Critical Nipro Corp
Application granted granted Critical
Publication of ATE476188T1 publication Critical patent/ATE476188T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03723352T 2002-05-14 2003-05-13 Medikament zur prävention und behandlung von familiärer amyloid polyneuropathie ATE476188T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002137944 2002-05-14
PCT/JP2003/005963 WO2003094934A1 (fr) 2002-05-14 2003-05-13 Médicament pour prévenir et traiter l'amyloïdose

Publications (1)

Publication Number Publication Date
ATE476188T1 true ATE476188T1 (de) 2010-08-15

Family

ID=29416833

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03723352T ATE476188T1 (de) 2002-05-14 2003-05-13 Medikament zur prävention und behandlung von familiärer amyloid polyneuropathie

Country Status (7)

Country Link
US (1) US20060134228A1 (de)
EP (1) EP1504762B1 (de)
CN (1) CN100457122C (de)
AT (1) ATE476188T1 (de)
AU (1) AU2003235261A1 (de)
DE (1) DE60333628D1 (de)
WO (1) WO2003094934A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1819354B1 (de) * 2004-08-26 2011-07-20 BioCrine AB Verfahren und verbindungen zur behandlung von diabetes
US10398729B2 (en) * 2012-02-14 2019-09-03 Kenneth O. Russell Method for treating Alzheimer's disease
WO2010030203A1 (en) * 2008-09-09 2010-03-18 Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr
CN103833628B (zh) * 2014-02-21 2016-05-11 河北富格药业有限公司 一种吡啶甲酸铬的合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276059A (en) * 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
GB9300920D0 (en) * 1993-01-19 1993-03-10 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
KR960037692A (ko) * 1995-04-13 1996-11-19 김광희 피콜린산-크롬 복합물의 새로운 제조방법
US5614224A (en) * 1995-04-20 1997-03-25 Womack; Rick W. Nutritional supplement for diabetics
CN1189776A (zh) * 1995-05-12 1998-08-05 营养21 大剂量给药用于治疗ⅱ型糖尿病的三吡啶甲酸铬
US6329361B1 (en) * 1995-05-12 2001-12-11 Nutrition 21 High-dose chromic picolinate treatment of type II diabetes
CA2257279A1 (en) * 1996-06-06 1997-12-11 Reuven Sandyk Compositions and method which retard the aging process and which improve age-related disease conditions
EP1006794B1 (de) * 1997-03-12 2007-11-28 Robert W. Esmond Verfahren zur behandlung oder prävention der alzheimerischen krankheit
US5888553A (en) * 1997-04-08 1999-03-30 Infinity, Inc. Non-steroidal anabolic composition
AU751431B2 (en) * 1997-08-08 2002-08-15 Nutrition 21 Chromium/biotin treatment of type II diabetes
US6143301A (en) * 1998-08-28 2000-11-07 Ambi Inc. Chromium picolinate compositions and uses thereof
US5980905A (en) * 1998-08-28 1999-11-09 Ambi Inc. Chromium polynicotinate compositions and uses thereof
AU6384099A (en) * 1998-08-31 2000-03-21 Proteotech, Inc. Blended compositions for treatment of alzheimer's disease and other amyloidoses
EP1113804A2 (de) * 1998-09-17 2001-07-11 Akesis Pharmaceuticals, Inc. Kombinationen des chroms oder des vanadiums mit antidiabetika für glukosemetabolismusstörungen
WO2000041686A1 (en) * 1999-01-12 2000-07-20 Seymour Ehrenpreis Treatment of hypertension with compounds that inhibit the destruction of enkephalins or endorphins
JP2005525401A (ja) * 2002-04-23 2005-08-25 ニュートリション ２１、インコーポレイテッド 薬剤誘発インスリン抵抗性を阻害するためのクロム組成物およびその使用方法

Also Published As

Publication number Publication date
EP1504762A4 (de) 2008-03-26
AU2003235261A1 (en) 2003-11-11
EP1504762B1 (de) 2010-08-04
WO2003094934A1 (fr) 2003-11-20
EP1504762A1 (de) 2005-02-09
CN100457122C (zh) 2009-02-04
DE60333628D1 (de) 2010-09-16
US20060134228A1 (en) 2006-06-22
CN1652803A (zh) 2005-08-10

Similar Documents

Publication Publication Date Title
DE60228761D1 (de) Pharmazeutische zusammensetzung (kit) enthaltend dihydropyridinonverbindungen und eine verbindung mit immunmodulatorischer (oder antiinflammatorischer) wirkung und ihre verwendung
ATE142489T1 (de) Zusammensetzung und verfahren zur prävention und behandlung von hypercholesterinämie und zellproliferationsstorungen
AU2003256755A1 (en) Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
ATE444077T1 (de) Präventiva und therapeutika für mit demyelinisierung-assozierten erkrankungen
ATE340568T1 (de) Verwendung einer pharmazeutischen formulierung enthaltend milchsäure oder laktat und kalium zur behandlung von hirnödem und verletzungen des gehirns
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
BRPI0417101A (pt) uso de compostos de peptìdeo para tratamento de dor neuropática central
ATE318606T1 (de) Zusammenstellungen zur prophylaxe und behandlung von allergien des typus i
DE60212613D1 (de) Doxycyclin zur behandlung von akne
ATE203402T1 (de) Verwendung von n-(2,6-dimethylphenyl)-2-(2-oxo-1- pyrrolidinyl)acetamid zur behandlung von demenz
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
ATE369130T1 (de) Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen
ATE412414T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen
ATE476188T1 (de) Medikament zur prävention und behandlung von familiärer amyloid polyneuropathie
DE60231969D1 (de) sPLA2-INHIBITOREN ZUR BEHANDLUNG VON ARTERIOSKLEROSE
ATE346597T1 (de) Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten
ATE289204T1 (de) Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie
PL1656131T3 (pl) Zastosowanie betainy w leczeniu chromania przestankowego
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
WO2001070683A3 (en) 3-substituted-4-pyrimidone derivatives
MXPA05014143A (es) Derivados de cumarina para el tratamiento de trastornos oftalmicos.
ATE333897T1 (de) Arzneimittel mit chymaseinhibitoren als wirksames mittel zur behandlung von dermatitis mit zweiphasigen hautreaktionen
EP0838220A4 (de) Arzneimittel zur heilung von gehirnerkrankungen
DE69932434D1 (de) Prophylaxe und Behandlung von autoimmunen Entmyelinisierungserkrankungen durch Fas-antagonisten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties